Important Copyright Message

The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints
or call customer service at: 800-211-2769
Back to the Future: Nesiritide (Natrecor)

A recent editorial in The New England Journal of Medicine commented on the negative results of a clinical trial (published in the same issue) of nesiritide, a drug that had been approved by the FDA in 2001 (conditionally approved by Health Canada in 2007) for relief of dyspnea in patients with acutely decompensated heart failure. The authors of the recent clinical trial concluded: “On the basis of these results, nesiritide cannot be recommended for routine use in the broad population of patients with acute heart failure.”1 The editorialist lamented the inadequacy of the data that had led to the approval of the drug in the first place, the 10 years of “fuzziness and ambiguity” that had followed regarding its use, and the “more than $1 billion” wasted on buying it.2

In 2001, when nesiritide was first approved in the US, The Medical Letter also expressed dissatisfaction with the quality of the data cited by the 2011 editorialist, and concluded its assessment of nesiritide as follows: “Until more published data become available, nesiritide should probably be reserved for treatment of patients with heart failure who have not responded to nitroglycerin and cannot be treated with nitroprusside.”3